Top View
- How to Order Chemotherapy at Shands at the University of Florida - Inpatient
- Chemogenomic Screening Identifies the Hsp70 Co-Chaperone HDJ2 As
- HOPA News Volume 10, Issue 1
- And Irinotecan (FOLFIRI)
- Phase I Study of Irinotecan Combined with Mitomycin-C and 5
- Topoisomerase II Inhibitors Induce Cgas-STING Dependent Inflammation Resulting In
- CAPIRI (XELIRI Or Irinotecan & Capecitabine)
- (XELIRI) Regimen • Colorectal Cancer– Capecitabine-Irino
- 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers—Letter Osamu Maeda, Tomoya Shimokata, and Yuichi Ando
- GICIRB Protocol
- Capecitabine and Mitomycin C in Patients with Metastatic Colorectal Cancer Resistant to Fluorouracil and Irinotecan
- Capecitabine and Irinotecan As First- Line Chemotherapy for Patients with Metastatic Colorectal Cancer
- Irinotecan, Topotecan, Paclitaxel Or Docetaxel for Second-Line Treatment of Small Cell Lung Cancer
- Evaluation of Irinotecan in Combination with 5-Fluorouracil Or Etoposide in Xenograft Models of Colon Adenocarcinoma and Rhabdomyosarcoma
- The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: a Phase I Trial
- WHO Model List of Essential Medicines
- Dose Banding As an Alternative to Body Surface Area-Based Dosing of Chemotherapeutic Agents
- Chemogenomic Screening Identifies the Hsp70 Co-Chaperone DNAJA1
- Gastric Cancer Treatment Regimens
- Acute Mucositis and Gastrointestinal Toxicity Caused by Radiotherapy Or Systemic Anti-Cancer Treatment 2019
- Relapsed/Progressive High-Risk Neuroblastoma
- GICAPIRI Protocol
- A Phase II Study of Weekly Irinotecan and Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer
- BRAIN CANCER TREATMENT REGIMENS (Part 1 of 9) Clinical Trials: the NCCN Recommends Cancer Patient Participation in Clinical Trials As the Gold Standard for Treatment
- Patient Support Program & Patient Assistance Enrollment Form
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- CAMPTOSAR (Irinotecan)
- Irinotecan Ver
- Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model
- Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
- Second-Line Treatment of Advanced Gastric Cancer: Current Options and Future Perspectives
- Treatment Strategy for Patients with Relapsed Small-Cell Lung Cancer: Past, Present and Future
- Global Oncology
- Relapsed Rhabdomyosarcoma
- Irinotecan Or Topotecan) Plus High-Dose Cyclophosphamide As Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma
- Irinotecan in Patients with Relapsed Or Cisplatin-Refractory Germ Cell Cancer: a Phase II Study of the German Testicular Cancer Study Group
- Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
- Hazardous Drug List
- Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: from Scientific Evidence to Clinical Application
- Irinotecan Plus Doxorubicin Hydrochloride Liposome For
- Tyrosine Kinase-Targeting Drugs-Associated Heart Failure